Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Antiplatelet Treatment with Dual Pathway Inhibition
Author(s): Tobias Geisler Added: 1 year ago

Anticoagulation

Prevention & Chronic Conditions
30th Annual Meeting of the ISCP
Author(s): Cristina Helguera Amezua , Laura Pérez Bacigalupe , Diego Manuel de la Eranueva , et al Added: 1 month ago

Prevention & Chronic Conditions

Anticoagulation
SCAI 25: Insights from the TRITAVI Registry
Author(s): Francesco Pelliccia Added: 1 year ago
SCAI 2025 - Insights from antiplatelet therapy after transcatheter aortic valve replacement (TAVR) show patients who received single antiplatelet treatment had significantly lower rates of overall six-month mortality, CV death and non-CV death compared to those treated with double antiplatelet treatment.Dr Francesco Pelliccia (Sapienza University of Rome, Rome, IT) joins us to discuss insights… View more

Anticoagulation

Intervention
ESC 24: EPIC-CAD: Edoxaban vs Dual Antiplatelet Therapy in AF & CAD
Author(s): Gi-Byoung Nam , Min Soo Cho Added: 1 year ago
ESC Congress 2024 — Edoxaban monotherapy significantly improves outcomes in high-risk patients with CAD and atrial fibrillation.Investigators, Dr Gi-Byoung Nam (Ulsan University Hospital, Ulsan, SK) and Dr Min Soo Cho (Asan Medical Center, Seoul, SK) join us to discuss the key findings from the EPIC-CAD trial (NCT03718559).This Korean multi-centre, open-labelled, randomised controlled study… View more

Anticoagulation

Electrophysiology & Arrhythmia
Sex Influences DAPT De-escalation Outcomes Post-PCI
Added: 1 month ago Source:  Interventional Cardiology
Mirjam Boros, Radcliffe CardiologyDe-escalation of dual antiplatelet therapy (DAPT) is a strategy used to improve outcomes after percutaneous coronary intervention (PCI).¹˒² However, the impact of patient sex on the safety and efficacy of these strategies has been unclear. A new network meta-analysis published in the European Heart Journal has investigated these potential differences… View more

Intervention

Anticoagulation
30th Annual Meeting of the ISCP
Author(s): Jordi Cahís , Pablo Carrión-Montaner , Jordi Sans , et al Added: 1 month ago

Prevention & Chronic Conditions
EuroPCR 24: The CAGEFREE II Trial
Author(s): Ling Tao Added: 2 years ago
EuroPCR 2024 — Investigator, Dr Ling Tao joins us to discuss the findings from the CAGEFREE II trial.Compared to drug-eluting stents, drug-coated balloons are associated with faster vessel healing and reduced thrombotic burden, therefore patients treated with DCBs require a less intensive antiplatelet therapy. CAGEFREE II investigated the effectiveness and safety of a tailored one-month DAPT… View more

Intervention
Author(s): Manav Sohal Added: 1 year ago

Anticoagulation

Electrophysiology & Arrhythmia
ACC 25: The SMART-CHOICE 3 Trial
Author(s): Joo-Yong Hahn Added: 1 year ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel… View more

Anticoagulation

Intervention
ACC 25: The Phase 3 REVERSE-IT Trial
Author(s): Deepak L Bhatt Added: 1 year ago
ACC 2025 - Phase three results of the use of bentracimab in patients who need urgent ticagrelor reversal show significantly restored platelet function as measured by percent inhibition of P2Y12 Reaction Unit (PRU).Dr Deepak L Bhatt (Mount Sinai Fuster Heart Hospital, New York, US) joins us onsite at ACC 2025 to discuss phase three results from the multi-center, open-label, single-arm REVERSE-IT… View more

Anticoagulation